DuoTrav® Eye Drops As Replacement Therapy Program

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00828906
First received: January 23, 2009
Last updated: September 18, 2012
Last verified: July 2012

January 23, 2009
September 18, 2012
February 2009
November 2009   (final data collection date for primary outcome measure)
Intra Ocular Pressure [ Time Frame: visit 1, Visits 2-3, Visits 6-8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00828906 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
DuoTrav® Eye Drops As Replacement Therapy Program
Not Provided

To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Open-angle Glaucoma
  • Ocular Hypertension
Drug: DuoTrav
DuoTrav Eye Drops
Experimental: 1
DuoTrav
Intervention: Drug: DuoTrav
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
128
Not Provided
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00828906
DART-2
No
Alcon Research
Alcon Research
Not Provided
Not Provided
Alcon Research
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP